DK2185698T3 - Kinaseinhibitorer og anvendelser deraf - Google Patents

Kinaseinhibitorer og anvendelser deraf Download PDF

Info

Publication number
DK2185698T3
DK2185698T3 DK08797416.8T DK08797416T DK2185698T3 DK 2185698 T3 DK2185698 T3 DK 2185698T3 DK 08797416 T DK08797416 T DK 08797416T DK 2185698 T3 DK2185698 T3 DK 2185698T3
Authority
DK
Denmark
Prior art keywords
kinase
peptide
seq
inhibiting
amino acid
Prior art date
Application number
DK08797416.8T
Other languages
English (en)
Inventor
Alyssa Panitch
Brandon Seal
Brian Ward
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of DK2185698T3 publication Critical patent/DK2185698T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (13)

1. Kinaseinhiberende sammensætning, der omfatter et kinaseinhiberende peptid til inhibering af vækst af et neoplasma, hvor det kinaseinhiberende peptid er et peptid med en aminosyresekvens valgt blandt gruppen bestående af HRRIKAWLKKIKALARQLGVAA [SEQ ID NO: 166]; WLRRIKAWLRRIKALARQLGVAA [SEQ ID NO: 113]; WLRRIKAWLRRALARQLGVA [SEQ ID NO: 177]; KAFAKLAARLYRKALARQLGVAA [SEQ ID NO: 173]; FAKLAARLYRKALARQLGVAA [SEQ ID NO: 163]; YARAAARQARAKALARQLGVAA [SEQ ID NO: 106]; YARAAARQARAKALNRQLGVA [SEQ ID NO: 28]; YARAAARQARAKALNRQLAVAA [SEQ ID NO: 100]; og YARAAARQARAKALNRQLAVA [SEQ ID NO: 64],
2. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens HRRIKAWLKKIKALARQLGVAA [SEQ ID NO: 166],
3. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens WLRRIKAWLRRIKALARQLGVAA [SEQ ID NO: 113],
4. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens WLRRIKAWLRRALARQLGVA [SEQ ID NO: 177],
5. Kinaseinhiberende sammensætning ifølge krav 1 til anvendelse i en fremgangsmåde til behandling af et neoplasma valgt blandt gruppen bestående af et papillom, et adenom, et hydatidiformmodermærke, et fibrom, et chondrom, et osteom, et leiomyom, et rhabdomyom, et lipom, et hemangiom, et lymphangiom, et polycythaemia vera, en infektiøs mononucleose, et "godartet giiom”, et menin-giom, et ganglioneurom, et neurilemmom, et neurofibrom, et pigmenteret næves (modermærke), et pheochromocytom, en carcinoid tumor, et te ratom, et carei-nom, et adenocarcinom, et basaiceiiecarcinom, et choriocarcinom, et fibrosar-kom, et cbondrosarkom, et osteosarkom, et leiomyosarkom, et rhabdomyosar-kom, et liposarkom, et hemangiosarkom, et lymphangiosarkom, en myeiocytisk leukemi, en erythrocytisk leukemi, en lymphocytisk leukemi, et multipelt myelom, en monocytisk leukemi, et Ewing sarkom, et ondartet non-Hodgkin iymfom, et meduliobiastom, oligodendrogliom, et neurilemmaisarkom, ondartet melanom, thymon, en gliobiastom multiforme, et astrocytom, et ependymom, et meningeal-sarkom, et neuroblastom (schwannom), et neurofibrosarkom, et ondartet pheochromocytom, et retinoblastom, en carcinoid tumor, en nephroblastom (Wilms tumor), et teratocarcinom og et embryonaicarcinom med choriocarcinom.
8. Anvendelse af den kinaseinhiberende sammensætning ifølge krav 1 i fremstillingen af et medikament til behandling af et neoplasma valgt blandt gruppen bestående af et papillom, et adenom, et hydatidiformmodermærke, et fibrom, et chondrom, et osteom, et leiomyom, et rhabdomyom, et lipom, et hemangiom, et lymphangiom, et polycythaemia vera, en infektiøs mononucleose, et "godartet” giiom, et meningiom, et ganglioneurom, et neurilemmom, et neurofibrom, et pigmenteret nævus (modermærke), et pheochromocytom, en carcinoid tumor, et te ratom, et card nom, et adenocarcinom, et basaiceiiecarcinom, et choriocarci-nom, et fibrosarkom, et chondrosarkom, et osteosarkom, et leiomyosarkom, et rhabdomyosarkom, et liposarkom, et hemangiosarkom, et lymphangiosarkom, en myeiocytisk leukemi, en erythrocytisk leukemi, en lymphocytisk leukemi, et multipelt myelom, en monocytisk leukemi, et Ewing sarkom, et ondartet non-Hodgkin Iymfom, et meduliobiastom, oligodendrogliom, et neurilemmaisarkom, ondartet melanom, thymon, en gliobiastom multiforme, et astrocytom, et ependymom, et meningeaisarkom, et neuroblastom (schwannom), et neurofibrosarkom, et ondartet pheochromocytom, et retinoblastom, en carcinoid tumor, en nephroblastom (Wilms tumor), et teratocarcinom og et embryonaicarcinom med choriocarcinom.
7. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhibe-rende peptid er en cyclinafhængig kinaseinhibitor.
8. Kinaseinhiberende sammensætning ifølge krav 1, hvor sammensætningen inducerer programmeret celledød af mindst en celle i en cellepopulation.
9. Kinaseinhiberende sammensætning ifølge krav 1, hvor sammensætningen inhiberer hyperplasi af mindst en hyperplastisk celle i en cellepopulation.
10. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens KAFAKLAARLYRKALARQLGVAA [SEQ ID NO: 173],
11. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens FAKLAARLYRKALARQLGVAA [SEQ ID NO: 163],
12. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALARQLGVAA [SEQ ID NO: 106],
13. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLGVA [SEQ ID NO: 28].
14. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLAVAA [SEQ ID NO: 100],
15. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhibe-rende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLAVA [SEQ ID NO: 64],
DK08797416.8T 2007-08-07 2008-08-07 Kinaseinhibitorer og anvendelser deraf DK2185698T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96394107P 2007-08-07 2007-08-07
US99497007P 2007-09-24 2007-09-24
PCT/US2008/072525 WO2009021137A2 (en) 2007-08-07 2008-08-07 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DK2185698T3 true DK2185698T3 (da) 2015-07-27

Family

ID=40342047

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08797416.8T DK2185698T3 (da) 2007-08-07 2008-08-07 Kinaseinhibitorer og anvendelser deraf

Country Status (6)

Country Link
US (2) US8741849B2 (da)
EP (1) EP2185698B1 (da)
JP (1) JP5703466B2 (da)
DK (1) DK2185698T3 (da)
ES (1) ES2547229T3 (da)
WO (1) WO2009021137A2 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007342674B2 (en) 2007-01-10 2013-09-19 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
CN102256613B (zh) * 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
BR112013026313A8 (pt) 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
CN102949722A (zh) * 2011-08-26 2013-03-06 中国医学科学院放射医学研究所 基于p38抑制剂和细胞生长因子的新颖药物组合物
EP2771069A4 (en) 2011-10-27 2015-08-26 Mayo Foundation INHIBITION OF G-PROTEIN-COUPLED RECEPTOR-6-KINASE POLYPEPTIDE
WO2013067050A1 (en) * 2011-10-31 2013-05-10 University Of Utah Research Foundation Genetic alterations in glioblastoma
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2014160364A1 (en) * 2013-03-13 2014-10-02 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
AU2014250830A1 (en) 2013-04-11 2015-11-12 Vanderbilt University Polyplexes
GB201314610D0 (en) * 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
CN103739678B (zh) * 2013-12-31 2015-09-02 刘培臣 抑制粘附斑激酶多肽及其应用
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
EP3134399A4 (en) 2014-04-21 2017-12-27 Mayo Foundation for Medical Education and Research Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
AU2015300966A1 (en) * 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
CN107106650A (zh) 2014-11-17 2017-08-29 莫伊莱麦屈克斯公司 用于预防或治疗表征为异常的成纤维细胞增殖和细胞外基质沉积的疾病、状况或过程的组合物和方法
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
JP2018512401A (ja) * 2015-03-12 2018-05-17 モイライ マトリックス インコーポレイテッド Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
WO2017147526A1 (en) 2016-02-26 2017-08-31 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11213857B2 (en) 2017-06-06 2022-01-04 Derrick Corporation Method and apparatus for screening
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
JP7644000B2 (ja) * 2018-05-15 2025-03-11 インテルク ペプチド セラピューティクス リミテッド 活性化剤
JP7386852B2 (ja) * 2018-05-15 2023-11-27 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
WO2020053812A1 (en) * 2018-09-12 2020-03-19 Purdue Research Foundation Alkynyl nicotinamide compounds as kinase inhibitors
CA3126143A1 (en) * 2019-01-11 2020-07-16 The Board Of Trustees Of The Leland Stanford Junior University Pi4-kinase inhibitors with anti-cancer activity
US12415788B2 (en) 2019-03-21 2025-09-16 The Board Of Trustees Of The Leland Stanford Junior University PI4-kinase inhibitors and methods of using the same
WO2021097407A2 (en) * 2019-11-15 2021-05-20 Regents Of The University Of Colorado, A Body Corporate Novel peptide compositions and methods of treating neurological injury
CN114605497B (zh) * 2021-02-10 2023-04-28 北京欣安诚科技有限公司 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
CN115976033B (zh) * 2022-12-14 2024-05-17 西南大学 瓜实蝇tssk1和tssk3基因及其应用
WO2025151669A1 (en) * 2024-01-10 2025-07-17 President And Fellows Of Harvard College Clk2 inhibition as a radiation countermeasure

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US5175144A (en) 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
WO1991016057A1 (en) 1990-04-18 1991-10-31 University Of Utah COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US7041814B1 (en) 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
JP2002510336A (ja) * 1998-04-11 2002-04-02 エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法
US7601685B2 (en) 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7615373B2 (en) 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP2004520088A (ja) 2000-08-15 2004-07-08 サーモディックス，インコーポレイティド 薬剤混和マトリックス
EP1351702B1 (en) 2000-12-08 2015-03-04 Bioprovar Corporation Trem-1 splice variant for use in modifying immune responses
WO2002057413A2 (en) 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
DE10118774A1 (de) 2001-04-17 2002-10-31 Jerini Ag Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
JP2005506836A (ja) 2001-08-23 2005-03-10 アリゾナ・ボード・オブ・リージェンツ 平滑筋治療用薬剤および方法
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
IL163575A0 (en) * 2002-02-21 2005-12-18 Univ Rockefeller Compositions and method for regulation of calcium-dependent signalling in brain
US20040005686A1 (en) 2002-03-07 2004-01-08 Pharmacia Corporation Crystalline structure of human MAPKAP kinase-2
US20070026518A1 (en) 2005-03-29 2007-02-01 The Regents Of The University Of California Controlling stem cell destiny with tunable matrices
US20030190364A1 (en) 2002-04-01 2003-10-09 Alyssa Panitch Biological affinity based delivery systems
US7364870B2 (en) 2002-08-02 2008-04-29 Wyeth MK2 interacting proteins
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
DE602004001509T2 (de) 2003-02-21 2007-02-15 Arizona Board Of Regents, Tempe Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
AU2004281838B2 (en) 2003-10-17 2008-01-31 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
US20060141528A1 (en) 2004-05-21 2006-06-29 Aebersold Rudolf H Compositions and methods for quantification of serum glycoproteins
AU2005332637B2 (en) 2004-07-23 2011-04-07 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
US20060115453A1 (en) * 2004-11-12 2006-06-01 Yaffe Michael B Methods and compositions for treating cellular proliferative diseases
US8008093B2 (en) 2004-12-02 2011-08-30 The University Of North Carolina At Chapel Hill Inhibition of Hsp27 phosphorylation for the treatment of blistering disorders
US7767642B2 (en) 2005-04-15 2010-08-03 Arizona Biomedical Research Commission Therapeutic peptides for the treatment of metastatic cancer
EP1948259B1 (en) 2005-10-26 2017-03-22 Genesis Technologies Limited Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products
CA2626868A1 (en) 2005-11-01 2007-05-10 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizo Na State University Novel protein transduction domains and uses therefor
WO2007062060A2 (en) 2005-11-22 2007-05-31 Ted Reid Methods and compositions using substance p to promote wound healing
EP2051727A4 (en) 2006-07-12 2012-03-14 Univ Arizona METHOD FOR THE TREATMENT OF FIBROTIC DISEASES AND KELOIDS
AU2007342674B2 (en) * 2007-01-10 2013-09-19 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
WO2009123759A2 (en) 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
BR112013026313A8 (pt) 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular

Also Published As

Publication number Publication date
US20130184221A9 (en) 2013-07-18
JP2010535508A (ja) 2010-11-25
HK1144306A1 (zh) 2011-02-11
EP2185698A4 (en) 2012-03-28
ES2547229T3 (es) 2015-10-02
JP5703466B2 (ja) 2015-04-22
EP2185698B1 (en) 2015-04-22
EP2185698A2 (en) 2010-05-19
WO2009021137A2 (en) 2009-02-12
US9447158B2 (en) 2016-09-20
US20140342993A1 (en) 2014-11-20
WO2009021137A3 (en) 2009-07-09
US8741849B2 (en) 2014-06-03
US20090149389A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
DK2185698T3 (da) Kinaseinhibitorer og anvendelser deraf
US9327008B2 (en) Cell-permeant peptide-based inhibitor of kinases
Jobson et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
US7157422B2 (en) Glycogen synthase kinase-3 inhibitors
WO2011160016A2 (en) E3 binding pockets and identification and use of e3 ligase inhibitors
Goel et al. The unique N‐terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1
AU2007233784A1 (en) Use of a kinase inhibitor for the treatment of particular resistant tumors
ES2252928T3 (es) Genes y proteinas ciclina e1.
Kumar et al. Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling
US20240083948A1 (en) Modified peptides and associated methods of use
HK1144306B (en) Kinase inhibitors and uses thereof
ES2313029T3 (es) Metodo para evaluar la actividad de fosforilacion de lkb1.
US6641994B2 (en) Methods of identifying anti-viral agents
AU2013202108B2 (en) Cell-permeant peptide-based inhibitor of kinases
AU2016201861B2 (en) Cell-permeant peptide-based inhibitor of kinases
US20240165113A1 (en) Methods of treatment for leukemia
JP4273232B2 (ja) サイクリン依存性キナーゼ５（Ｃｄｋ５）特異的ペプチド性阻害剤
HK1163449B (en) Cell-permeant peptide-based inhibitor of kinases
CN117957239A (zh) 癌症治疗剂
WO2006001275A1 (ja) グリコーゲン合成酵素を直接活性化する化合物をスクリーニングする方法
US20060084600A1 (en) Human homologues of fused gene
US20040121463A1 (en) Methods and compositions for modulating apoptosis
HK1129039A (en) Use of a kinase inhibitor for the treatment of particular resistant tumors